## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Britta HARDY et al

Serial No.:

10/577,679

Filed:

April 28, 2006

For:

ANGIOGENIC PEPTIDES AND USES THEREOF

Examiner:

Not yet Assigned

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 \$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$

Group Art Unit: 1654

Attorney

Docket: 31831

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: February 11, 2007



Signature

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Accounts a rerequired to respond to a collection of information unless it contains a valid OMB control number.

|  |          | a Act and a collection of  | Comp   | lete if Known      |  |  |
|--|----------|--|--|--------------------|--|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary) |          |  | Application Number   |                    |  |  |
|  |          |  | Filing Date  | April 28, 2006     |  |  |
|  |          |  | First Named Inventor   | Britta HARDY et al |  |  |
|  |          |  | Group Art Unit   | 1654               |  |  |
|  |          |  | Examiner Name  | Not Yet Assigned   |  |  |
| Sheet  | 11       | Of 1   | Attorney Docket Number   | 31831              |  |  |
|  | <u> </u> | OTHER PRIOR ART – NON PATE   | NT LITERATURE DOCU   | MENTS              |  |  |
| Examiner   | Cite     | Include name of the author (in CAPITAL LETTERS                                   |  |                    |  |  |
| Initials   | No.1     | item (book, magazine, journal, serial symposium, ca<br>publisher, city and/or co | untry where published.   | published.         |  |  |
|  | 1        | Puzas "Human TRAP Peptide SEQ ID NO: 24", Database Geneseq 'Online!,             |  |                    |  |  |
|  |          | Database Accession No. ABR44764, 2003. Abstract.                                 |  |                    |  |  |
|  | 2        |  | inbridge et al. "A Peptide Encoded by Exon 6 of VEGF (EG3306) Inhibits VEGF- |                    |  |  |
|  |          | IncludedAngiogenesis In Vitro and Ischaemic Retinal Neovascularisation In Vivo", |  |                    |  |  |
|  |          | Biochemidal and Biophysical Research Communications, 302: 793-799, 2003.         |  |                    |  |  |
|  | 3        | Conway et al. "Molecular Mechanisms of Blood Vessel Growth", Cardiovascular      |  |                    |  |  |
|  |          | Research, 49: 507-521, 2001.   |  |                    |  |  |
|  | 4        | Giordano et al. "Biopanning and Rapid Analysis of Selective Interactive          |  |                    |  |  |
|  |          | Ligands", Nature Medicine, 11(7), 1249-1253, 2001.                               |  |                    |  |  |
|  | 5        |  | e Isolated from a Phage Display Library Inhibits Tumor                       |                    |  |  |
|  | ]        | Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth     |  |                    |  |  |
|  |          | Factor to its Kinase Domain Receptor", The Journal of Biological Chemistry,      |  |                    |  |  |
|  |          | 277(45): 43137-43142, 200 2.   |  |                    |  |  |
|  | 6        | Liu et al. "Combinataorial Peptide Library                                       | Peptide Library Methods for Immunobiology Research",                         |                    |  |  |
|  |          | xperimental Hematology, 31: 11-30, 2003.   |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  |          |  |  |                    |  |  |
|  | <u> </u> |  |  |                    |  |  |
| -  |          |  |  |                    |  |  |
|  | _        |  |  |                    |  |  |
|  |          |  |  | -                  |  |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is unique citation designation number (optional).

3. Applicant's unique citation designation number (optional).

3. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered